• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Why is Amgen IC so bad?

Quote












ZS runs the show at Amgen, makes things complicated so that they secure more work to fix their own mess. Cost of IC consultants is close to the IC budget of a small sales force. No bueno. Just divide up the money and call it a day.
 




































IC issues have continued to plague the IBU for the last 5+ years. The inability of our internal folks to properly address these issues is driving good reps away from this company. When glaring issues are raised that should be fixed they do nothing…leaving some of us in crap positions that we will never dig out of. Amgen is buying less and less payer data and always promises that it’s “taken out of our baselines”. But…we know it’s an incredibly flawed system. Those winning Chairman’s repeatedly are mostly just in golden territories with the stars aligning for them.
 




anonymous said:
IC issues have continued to plague the IBU for the last 5+ years. The inability of our internal folks to properly address these issues is driving good reps away from this company. When glaring issues are raised that should be fixed they do nothing…leaving some of us in crap positions that we will never dig out of. Amgen is buying less and less payer data and always promises that it’s “taken out of our baselines”. But…we know it’s an incredibly flawed system. Those winning Chairman’s repeatedly are mostly just in golden territories with the stars aligning for them.
Click to expand...

The low base pay and lack of RSU is what drives the good people away. The bonus is about industry average.
 




anonymous said:
IC issues have continued to plague the IBU for the last 5+ years. The inability of our internal folks to properly address these issues is driving good reps away from this company. When glaring issues are raised that should be fixed they do nothing…leaving some of us in crap positions that we will never dig out of. Amgen is buying less and less payer data and always promises that it’s “taken out of our baselines”. But…we know it’s an incredibly flawed system. Those winning Chairman’s repeatedly are mostly just in golden territories with the stars aligning for them.
Click to expand...


IBU IC is as bad as it gets anywhere. Constant problems with baselines. When you point it out, it takes some time to hear back and the answer is always we took it out. But on myIC, nothing changes with my baselines. Too much missing data. I will have a critical SP reporting and it will just disappear. Guess what doesn't disappear? My baseline.

Half my district is entertaining other opportunities 100% because of IC.
 








anonymous said:
IBU IC is as bad as it gets anywhere. Constant problems with baselines. When you point it out, it takes some time to hear back and the answer is always we took it out. But on myIC, nothing changes with my baselines. Too much missing data. I will have a critical SP reporting and it will just disappear. Guess what doesn't disappear? My baseline.

Half my district is entertaining other opportunities 100% because of IC.
Click to expand...


Well, if you find somewhere with a good IC, please share. I've been on an IC team at almost every company that I have worked for - all were worthless. No one in commercial either cares to understand or is too stupid to understand the calculations, and the same goes for the operations/analytics people regarding how things actually work in the field. I have seen some really unbelievable BS - like analytics claiming that all territories have the same market size. Well, when we got the actual data, they were not even CLOSE to being similar, but analytics was creating the goals based on the assumption that they were. Do you think they changed anything then? A teeny, tiny bit. The dorks in ops/analytics have their own little association meetings and basically settle on the same crappy comp plans for every pharma company.
 




Amgen's problem is that when they lose reporting, they don't care enough to remove the corresponding baselines. The dorks who run IC hate reps with a passion and their response is always, "maybe you aren't selling as much as before!"

Amgen can't control what SPs do with reporting (just look at Accredo), but they can control removing the baselines. Sadly, they don't.
 












Top Bottom
Back
Quote